Peptide LexiconAll compounds

PNC-27: The Laboratory Anti-Cancer Peptide Built From a Piece of p53 — and No Human Trial Yet

PNC-27 is a synthetic peptide that joins residues 12–26 of the tumour-suppressor protein p53 to a membrane-penetrating segment. In cell and mouse studies it binds the HDM-2 protein on the surface of cancer cells and punches holes in their membranes. ClinicalTrials.gov lists no study of it in people.

Research compoundNot approved anywhere foundNo registered human trial

Caroline S · Published 2026-11-18

Length

C188H293N53O44S, molecular weight 4,032 (PubChem CID 16201774)

Sequence

Two parts: the HDM-2-binding domain of p53 (residues 12–26) and a transmembrane-penetrating domain (Sarafraz-Yazdi 2010, PMID 20080680); a related peptide in the same family carries the penetratin sequence (Bowne 2008, PMID 18931881)

Origin

Synthetic; developed by a group at SUNY Downstate Medical Center, Brooklyn, publishing from 2004 (PMID 14967026)

Last reviewed

2026-11-18

What is it good for?

Nothing in people yet. PNC-27 is a laboratory anti-cancer peptide: in cell cultures and in mice it killed cancer cells that carry the HDM-2 protein in their outer membranes while sparing the normal cells tested. No result in a human patient has been published, and ClinicalTrials.gov lists no study of it.

Illustration: An empty, clear glass test tube on a white lab bench with a deep green background and copper reflection.
Illustration

What it is

PNC-27 is a laboratory peptide built from a piece of p53, the best-known tumour-suppressor protein. It joins two segments: the stretch of p53 from residue 12 to residue 26, which is the part p53 uses to dock onto a protein called HDM-2 (the human version of MDM-2), and a transmembrane-penetrating domain that carries the peptide into and across cell membranes (Sarafraz-Yazdi 2010, PNAS, PMID 20080680). PubChem lists it as C188H293N53O44S, molecular weight 4,032 (CID 16201774).

HDM-2 normally lives inside the cell, where it switches p53 off. The PNC-27 idea runs the other way: the developers report that many cancer cells also carry HDM-2 in their outer membrane, where normal cells do not, and use the p53 fragment as a homing device for it.

The peptide comes from one research group, at SUNY Downstate Medical Center in Brooklyn, whose first structural paper on the p53 fragment appeared in 2004 (Rosal 2004, Biochemistry, PMID 14967026). Most of the later literature carries the same senior authors.

How it is said to work

Step What the papers report Source
Shape The p53 residues inside PNC-27 take the same 3D shape as p53 does when bound to HDM-2 Sarafraz-Yazdi 2010
Target HDM-2 found in the membranes of several cancer cell lines, not in untransformed lines Sarafraz-Yazdi 2010
Test of the target Normal breast cells resistant to PNC-27 became susceptible once full-length HDM-2 was placed on their surface Sarafraz-Yazdi 2010
Result Pores in the membrane, then rupture (necrosis), not programmed cell death Bowne 2008 on PNC-28 (PMID 18931881); Sookraj 2010 (PMID 20182728)

The group has named the mechanism "poptosis" — peptide-induced transmembrane pore formation — in a 2024 review led by Pincus, senior author of the 2010 paper (Biomedicines, PMID 38927351). The term is theirs; it is not a recognised category of cell death outside this literature.

What the evidence shows

All of it is pre-clinical. PubMed holds 23 records that match "PNC-27"; two of them are unrelated studies (child mortality in Nigeria, air pollution in Rome) that simply contain the string, which leaves about 21 on the peptide. None is a human trial.

Kind of study Examples Human?
Cancer cell lines ovarian, cervical, colon and leukaemia lines, plus breast lines in the 2010 paper (2010–2025, mostly in Ann Clin Lab Sci) No
Patient tumour tissue in the dish ovarian cancer cells taken from patients (Sarafraz-Yazdi 2015, PMID 26663795) Tissue only
Mice acute myeloid leukaemia transplant models, human and mouse (Wang 2020, Leukemia, PMID 31337857) No
People none found —

The 2020 Leukemia paper, from City of Hope in California rather than the Brooklyn group, is the strongest single result. PNC-27 killed both bulk leukaemia cells and the leukaemia stem cells that drive relapse, in primary and secondary transplant experiments, while normal blood-forming stem cells in wild-type mice kept their activity. Its conflict-of-interest statement records that Oncolyze, Inc. provided the PNC-27 used.

What is not established: whether membrane HDM-2 is present on human tumours inside the body at the levels seen in cell lines; what dose reaches a tumour; how long the peptide survives in human blood; and whether the sparing of normal cells holds in a person. No paper reports any of these in humans.

Where it stands

PNC-27 is not approved anywhere found. Drugs@FDA holds no application for it, and ClinicalTrials.gov listed no registered study on 2026-11-18. Any material labelled PNC-27 outside a research laboratory has had its identity, purity and sterility checked by no regulator.

Other peptides in the library that act on membranes include melittin from bee venom and the human antimicrobial peptide LL-37. FOXO4-DRI is another research peptide with a mouse-only record that sells far ahead of its evidence.

Sources opened 2026-11-18: Sarafraz-Yazdi 2010, PNAS (PMID 20080680, abstract); Wang 2020, Leukemia (PMID 31337857, abstract and conflict statement); PubMed E-utilities record list for "PNC-27" (23 records, titles read), including Rosal 2004 (PMID 14967026), Bowne 2008 (PMID 18931881), Sookraj 2010 (PMID 20182728), Sarafraz-Yazdi 2015 (PMID 26663795) and Pincus 2024 (PMID 38927351) by title; PubChem CID 16201774; ClinicalTrials.gov API v2; openFDA Drugs@FDA.

What the research shows

Kills cancer cells but not normal cells in culture

Sarafraz-Yazdi 2010, PNAS (PMID 20080680): membrane HDM-2 found in several cancer cell lines, not in untransformed lines; normal breast cells became susceptible only after HDM-2 was forced onto their surface

Clears leukemia cells in mice

Wang 2020, Leukemia (PMID 31337857): PNC-27 killed AML blasts and leukemia stem cells in human and mouse transplant models and spared normal blood stem cells; the peptide was supplied by Oncolyze, Inc

Treats cancer in people

No human study found: ClinicalTrials.gov returns 0 records for PNC-27 and PubMed 0 randomised trials (2026-11-18)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

No application in Drugs@FDA; openFDA returns no record for PNC-27 (2026-11-18). Not an approved medicine.

Trials

ClinicalTrials.gov: 0 studies (API v2 search, 2026-11-18).

Published record

PubMed: 23 records match 'PNC-27' in title or abstract, of which two are unrelated studies that share the string; 0 randomised trials (2026-11-18).

Frequently asked questions

What is PNC-27?

A synthetic peptide made of two parts: a 15-residue piece of the tumour-suppressor protein p53 that binds a protein called HDM-2, and a segment that lets the peptide cross cell membranes. It is a laboratory anti-cancer candidate, not an approved drug.

How is PNC-27 said to work?

Its p53 piece binds HDM-2, which the developers found sitting in the outer membranes of many cancer cells but not normal ones. Bound there, the peptide forms pores and the cell bursts. The group calls this 'poptosis' in a 2024 review.

Has PNC-27 been tested in humans?

No published human study was found. ClinicalTrials.gov returned no registered trial on 2026-11-18, and every result in PubMed comes from cell cultures, patient tissue in the dish, or mice.

What did the mouse studies show?

In a 2020 Leukemia paper, PNC-27 killed leukemia cells and leukemia stem cells in mouse transplant models, including human leukemia grown in mice, while normal blood-forming stem cells kept working. The authors noted the peptide was supplied by Oncolyze, Inc.

Is PNC-27 the same as PNC-28?

They are relatives from the same Brooklyn laboratory. PNC-28 also carries the penetratin sequence, and a 2008 study used it to show that the killing is membrane rupture rather than programmed cell death. Results for one should not be read across to the other without checking.

Is PNC-27 legal to buy?

It is not an approved medicine in the United States — Drugs@FDA holds no application for it — so it cannot be sold as a treatment. Any material labelled PNC-27 outside a laboratory supply chain has had its identity and purity checked by no regulator.